Quantitative Analysis of Cancer-associated Gene Methylation Connected to Risk Factors in Korean Colorectal Cancer Patients

Ho-Jin Kang¹, Eun-Jeong Kim¹, Byoung-Gwon Kim³, Chang-Hun You¹, Sang-Yong Lee², Dong-Il Kim³, Young-Seoub Hong¹

¹Department of Preventive Medicine, Dong-A University College of Medicine, Busan; ²Institute of Forensic Medicine, Pusan National University School of Medicine, Busan; ³Department of Occupational Medicine, Kangbuk Samsung Hospital, Seoul, Korea

Objectives: The purpose of this paper was to elucidate the potential methylation levels of adjacent normal and cancer tissues by comparing them with normal colorectal tissues, and to describe the correlations between the methylation and clinical parameters in Korean colorectal cancer (CRC) patients.

Methods: Hypermethylation profiles of nine genes (RASSF1, APC, p16INK4a, Twist1, E-cadherin, TIMP3, Smad4, COX2, and ABCB1) were examined with 100 sets of cancer tissues and 14 normal colorectal tissues. We determined the hypermethylation at a given level by a percent of methylation ratio value of 10 using quantitative methylation real-time polymerase chain reaction.

Results: Nine genes’ hypermethylation levels in Korean CRC patient tissues were increased more higher than normal colorectal tissues. However, the amounts of p16INK4a and E-cadherin gene hypermethylation in normal and CRC tissues were not significantly different nor did TIMP3 gene hypermethylation in adjacent normal and cancer tissues differ significantly. The hypermethylation of TIMP3, E-cadherin, ABCB1, and COX2 genes among other genes were abundantly found in normal colorectal tissues. The hypermethylation of nine genes’ methylation in cancer tissues was not significantly associated with any clinical parameters. In Cohen’s kappa test, it was moderately observed that RASSF1 was related with E-cadherin, and Smad4 with ABCB1 and COX2.

Conclusions: This study provides evidence for different hypermethylation patterns of cancer-associated genes in normal and CRC tissues, which may serve as useful information on CRC cancer progression.

Key words: Hypermethylation, Colorectal neoplasms, Genetic markers

INTRODUCTION

Colorectal cancer (CRC) arises due to genetic alterations through gene mutations and methylation and transforms colorectal epithelial cells into colorectal adenocarcinoma cells [1]. CRC is suitable for early detection approaches because it is recognizable at early stages [2]. Early detection of CRC appears to be most important in reducing mortality [3]. Therefore, molecular studies on epigenetic changes including CRC instability and DNA methylation have both been investigated for better understanding of CRC progression [4,5].

DNA methylation effects of a number of mediating genes in CRC development and the significance of the aberrant methylation in CRC have been reported [3,6,7]. The hypermethylation of several promoters including APC, p16INK4a, and TIMP3 in CRC [8,9] and the methylation-induced silencing of cancer
suppressor genes were investigated by a quantitative approach [10]. A quantitative approach toward methylation changes with normal and cancer tissues could provide useful information for a panel of DNA methylation markers for the detection of cancer occurrence.

In this study, we evaluate the potential methylation of cancer-associated genes concerned with cell cycle control, invasion, cancer progression, drug metabolism, and inflammation in Korean CRC tissues. Subsequently, we compare the methylation statuses of selected genes in CRC and fourteen samples of normal colorectal tissue and examine whether the amount of hypermethylation is associated with clinical parameters of CRC patients.

METHODS

Tissue Samples
A total of 100 paired CRC tissue samples containing adjacent normal tissue were obtained from CRC patients at Dong-A University Hospital in Busan, Korea. The diagnosis of CRC tissues was acquired from pathology reports and histological evaluations. Fourteen normal colorectal tissue samples were obtained from dead victims of traffic accidents who had agreed to body donation for medical research and education. Age and sex distributions were not significantly different among the subjects in the patient and normal groups. The design of this study was approved by the Committee on Human Research of Dong-A University. Every fresh tissue sample was frozen in liquid nitrogen right after the resection and storage in a deep refrigerator at -80°C.

Genomic DNA Extraction and Modification
Genomic DNA was extracted by means of a QIAamp DNA mini kit (Qiagen, Valencia, CA, USA). The tissue samples were ground with a pestle in liquid nitrogen and treated with 700 μL of a lysis buffer containing 20 μg/mL LaboPass protease K (Cosmo Gene Tech, Seoul, Korea), 20 mM Tris-HCl (pH 8.0), 5 mM EDTA (pH 8.0), 400 mM NaCl and 1% SDS solution (Sigma, St. Louis, MO, USA). The samples were then incubated in a 42°C incubator overnight. After incubation, the genomic DNA was purified three times via phenol/chloroform extraction. It was then eluted with 300 μL of water. The DNAs were quantified with a NanoDrop ND-100 device (Thermo Fisher Scientific, Waltham, MA, USA).

DNA modification was performed by means of an EZ DNA modification kit (Zymo-Research, Orange, CA, USA) following the manufacturer’s recommended procedure. One microgram of the extracted DNA was mixed with up to 50 μL of sodium-bisulfite containing 5 μL of M-dilution buffer. This mixture was then incubated for 15 minutes at 37°C in an incubator. One hundred microliters of CT conversion reagent containing M-dilution buffer was added to each sample and this was incubated for 15 hours at 50°C in an incubator without light. After this 15 hours incubation period, the DNA samples were placed on ice for 10 minutes. They were then transferred into Zymo-spin IC columns, treated with 400 μL of M-binding buffer, and then centrifuged at 13 000 rpm for 30 seconds. After discarding the flow-through material, 200 μL of M-wash buffer was added to the columns, and the resultant solution was centrifuged at 13 000 rpm for 30 seconds. After washing, 200 μL of M-desulfonation buffer was added to the samples. The samples were subsequently incubated at room temperature for 15 minutes and then centrifuged at 13 000 rpm for 30 seconds. Each column was washed two times with 200 μL of M-wash buffer. The modified genomic DNA was eluted using 30 μL of water.

Primer and Probes for Quantitative Methylation Reverse Transcription Polymerase Chain Reaction
We used previously reported primer and probe sequences for nine cancer associated genes [11-13]. These sequences are summarized in Table 1. Amplification of bisulfite-converted ACTB was used for the normalization of the input DNA. The negatives for the ACTB samples were excluded from the methylation analysis. A plasmid containing a bisulfite-converted ACTB gene of a known concentration was drawn at 1, 1/4, 1/16, 1/64, and 1/256 via serial dilutions. This was used as the standard curve for quantification.

Reverse transcription polymerase chain reaction (RT-PCR) was performed by TaqMan gene assays by means of a 7200 HT Fast real-time PCR system (Applied Biosystems, Foster City, CA, USA) and FAM-labeled probes (Table 1). Each PCR program started with an initial denaturation at 95°C for 10 minutes, followed by 45 cycles of denaturation at 95°C for 15 seconds, and annealing/extension at 60°C for 1 minute. Sodium-bisulfite treated CpGenome universal methylated DNA (Chemicon, Temecula, CA, USA) was used as a positive control. Relative quantization of the amplified gene levels in the tested genomic DNA samples was made by measuring the threshold cycle (Ct) values of the target genes and the beta-actin. The mean quantity of the genes was divided by the mean quantity of the ACTB. The RT-PCR reaction was duplicated.
Gene Promoter Methylation in Colorectal Cancer

**Statistical Analysis**

Hypermethylation was determined by the percentage of methylation ratio (PMR), and PMR values over 4% (PMR 4) or 10% (PMR 10) were utilized [14-17]. In our study, a PMR value was defined as \( \frac{[\text{gene}]_{\text{sample}}}{[\text{ACTB}]_{\text{sample}}} \times \frac{[\text{ACTB}]_{\text{control}}}{[\text{gene}]_{\text{control}}} \times 100 \) and hypermethylation of each gene was defined by PMR 10. The significance of the differences in the methylation ratio (i.e., PMR) and hypermethylation frequencies among normal tissues, adjacent normal tissues, and cancer tissues was evaluated with a t-test, chi-squared test, and Fisher’s exact test using SPSS version 12.0 (SPSS Inc., Chicago, IL, USA). All of the statistical tests were two-sided, and the statistical significance was deemed acceptable at \( p < 0.05 \). Cohen’s kappa statistic was used to measure the agreement among the methylation of nine gene promoters (PMR cut-off value of 10). The kappa values were interpreted as follows: <0.2, poor observer agreement; 0.2 - 0.4, fair observer agreement; 0.4 - 0.6, moderate observer agreement; 0.6 - 0.8, substantial observer agreement; and 0.8 - 1.0, good observer agreement [18].

**RESULTS**

We performed the statistical analysis by defining the proportion of hypermethylation as a given PMR value of 10 (PMR 10). The hypermethylation of nine cancer-associated genes showed an increase in the adjacent normal and cancer tissues among CRC patients compared with normal colorectal tissues (Figure 1). The hypermethylation of nine genes for both adjacent normal and cancer tissues in CRC patients was higher more in increased than that for normal tissues. However, the amounts of p16\(^{INK4a} \) and E-cadherin gene hypermethylation in normal and cancer tissues were not significantly different and TIMP3 gene hypermethylation was not significantly different in adjacent normal and cancer tissues (Figure 1). The average PMR values and hypermethylation frequencies from the quantitative methylation RT-PCR are summarized in Table 2. Among the nine cancer-associated genes, hypermethylation of TIMP3, E-cadherin, ABCB1, and COX2 genes were abundantly found in normal colorectal tissues within the PMR 10. However, the average PMR values of each gene other than E-cadherin were higher in the cancer tissues than in the normal tissues (Table 2). The p16\(^{INK4a} \) gene hypermethylation frequencies for the ad-
adjacent normal and cancer tissues with PMR 10 were 10% and 14%, respectively. No significant difference was revealed (Table 2) ($p > 0.05$). The association between hypermethylation and clinical parameters in the 100 CRC patients in accordance with PMR 10 is presented in Table 3. The hypermethylation of nine cancer-associated genes in CRC tissues was not associated with any clinical parameters including age, gender, smoking status, alcohol intake, or cancer staging. With Cohen’s kappa test, it was observed that RASSF1 was moderately related to E-cadherin, and Smad4 with ABCB1 and COX2 (Table 4).

**DISCUSSION**

In the current study, the main objective was to elucidate the potential methylation levels of adjacent normal and cancer tissues by comparing them with normal colorectal tissues in Korean CRC patients. In addition, we sought DNA methylation profiles and their association with clinical parameters in CRC. The hypermethylation of eight cancer-associated genes, that is, all except for the E-cadherin gene, was higher in adjacent normal and cancer tissues than that in normal colorectal tissues, suggesting a fundamental role in the methylation of
### Table 2. Average PMR and hypermethylation frequency over PMR 10 according to gene and tissue type

| Genes | Tissues (n) | Average PMR (%) | PMR 10 frequency | p-value |
|-------|-------------|-----------------|------------------|---------|
|       |             | Average         |                  |         |
|       |             | PMR (%)         |                  |         |
| APC   | Nr (14)     | 5.0             | 2 (14.3)         | <0.01   |
|       | Adj (100)   | 13.5            | 38 (38.0)        | <0.01   |
|       | Tu (100)    | 38.6            | 52 (52.0)        | <0.01   |
| p16INK4 | Nr (14)      | 1.4             | 0 (0.0)          | 0.02    |
|       | Adj (100)   | 5.5             | 10 (10.0)        | <0.01   |
|       | Tu (100)    | 8.8             | 14 (14.0)        | <0.01   |
| RASSF1A | Nr (14)     | 1.0             | 0 (0.0)          | <0.01   |
|       | Adj (100)   | 3.1             | 9 (9.0)          | <0.01   |
|       | Tu (100)    | 7.0             | 20 (20.0)        | <0.01   |
| Twist1 | Nr (14)     | 3.0             | 1 (7.1)          | 0.01    |
|       | Adj (100)   | 22.0            | 41 (41.0)        | 0.36    |
|       | Tu (100)    | 49.0            | 58 (58.0)        |         |
| TIMP3  | Nr (14)     | 12.2            | 9 (64.3)         | <0.01   |
|       | Adj (100)   | 36.2            | 62 (62.0)        | <0.01   |
|       | Tu (100)    | 44.5            | 43 (43.0)        |         |
| E-cadherin | Nr (14)    | 11.9            | 11 (78.6)        | 0.01    |
|       | Adj (100)   | 7.5             | 29 (23.0)        | 0.49    |
|       | Tu (100)    | 8.7             | 28 (28.0)        |         |
| ABCB1  | Nr (14)     | 14.5            | 8 (57.1)         | <0.01   |
|       | Adj (100)   | 11.0            | 30 (30.0)        | 0.36    |
|       | Tu (100)    | 60.1            | 69 (69.0)        |         |
| COX2   | Nr (14)     | 10.0            | 9 (64.3)         | <0.01   |
|       | Adj (100)   | 19.0            | 27 (27.0)        | 0.01    |
|       | Tu (100)    | 40.0            | 51 (51.0)        |         |
| Smad4  | Nr (14)     | 1.6             | 0 (0.0)          | <0.01   |
|       | Adj (100)   | 8.0             | 19 (19.0)        | <0.01   |
|       | Tu (100)    | 21.0            | 39 (39.0)        | <0.01   |

The p-value was calculated by a t-test using the average PMR. PMR, percentage of methylation ratio; PMR 10, a percent of methylation ratio over 10%; Nr, normal colorectal tissues; Adj, adjacent normal colorectal tissues; Tu, colorectal cancer tissues.

### Table 3. Hypermethylation frequencies over PMR 10 of nine cancer-associated genes with clinical parameters in 100 colorectal cancer tissues

| Gene | PMR 10 (%) | Average PMR (%) | PMR (%) | p-value | Age (y) | Gender | Smoking | Staging |
|------|------------|-----------------|---------|---------|---------|--------|---------|---------|
| APC  | 70 (70.0)  | 28 (28.0)       | 28 (28.0)|         |
|       | 60 (60.0)  | 25 (25.0)       | 25 (25.0)|         |
|       | 50 (50.0)  | 20 (20.0)       | 20 (20.0)|         |
| E-cadherin | 20 (20.0)  | 10 (10.0)       | 10 (10.0)|         |
|       | 30 (30.0)  | 15 (15.0)       | 15 (15.0)|         |
|       | 40 (40.0)  | 20 (20.0)       | 20 (20.0)|         |
| ABCB1 | 20 (20.0)  | 10 (10.0)       | 10 (10.0)|         |
|       | 30 (30.0)  | 15 (15.0)       | 15 (15.0)|         |
|       | 40 (40.0)  | 20 (20.0)       | 20 (20.0)|         |
| COX2  | 20 (20.0)  | 10 (10.0)       | 10 (10.0)|         |
|       | 30 (30.0)  | 15 (15.0)       | 15 (15.0)|         |
|       | 40 (40.0)  | 20 (20.0)       | 20 (20.0)|         |
| Smad4 | 20 (20.0)  | 10 (10.0)       | 10 (10.0)|         |
|       | 30 (30.0)  | 15 (15.0)       | 15 (15.0)|         |
|       | 40 (40.0)  | 20 (20.0)       | 20 (20.0)|         |

The p-value was calculated by a chi-squared test and Fisher's exact test. PMR 10, a percent of methylation ratio over 10%; Nr, normal colorectal tissues; Adj, adjacent normal colorectal tissues; Tu, colorectal cancer tissues.

Cancer-associated genes in Korean CRC patients.

The APC gene mechanisms are associated with gene inactivation by promoter hypermethylation, and may also play a role in the loss of APC function in tumors [6,19]. The promoter region of the APC gene is highly methylated in colorectal carcinoma compared to normal colorectal mucosa and premalignant adenomas [20]. In addition, Rashid et al. [7] reported that methylation was more frequent in adenomas with tubulo-villous or villous histology. APC hypermethylation has been also considered an early step in the process of CRC pathogenesis and cross-talk with the WNT/β-catenin pathway [8,21]. Likewise, in the present study, an APC gene methylation state was...
observed in CRC tissues and adjacent normal tissues. These results may be supported by the finding that APC hypermethylation may ultimately lead to tumor development [22]. Cyclooxygenase2 (COX2 or PTGS2) was also engaged in cross-talk with the WNT/β-catenin pathway [23]. Castells et al. [24] have reported that the hypermethylation of COX2 appears to be the most attractive explanation for the lack of COX2 overexpression in cancer patients. In addition, COX2 promoter hypermethylation was significantly associated with a lack of COX2 expression. We have determined that COX2 hypermethylation may support regulatory mechanisms in CRC. Thus, the evidence suggests that the COX2 hypermethylation mechanism is involved in the response to COX2 gene silencing. In our additional data, the APC and COX2 promoter methylation in CRC tissues was not significantly associated with any clinical parameters such as age, gender, or smoking status according to PMR 10. Lin et al. [25] showed that APC promoter methylation was significantly higher in cancerous tissues than non-cancerous tissues, but the methylation status had no clear relationship with clinical parameters. APC and COX2 methylation studies are needed to confirm the findings on the association with clinical parameters by a sufficient number of subjects.

Previous studies have reported the aberrant methylated incidence associated with inactivation of p16INK4a in CRC [18,26]. Wiencke et al. [27] reported that methylation of p16INK4a was associated with anatomical location, gender, age, and poorly differentiated adenocarcinoma. Ishiguro et al. [28] also observed the methylation of p16INK4a in 20/88 (22.7%) of cancer tissues, but the frequency of p16INK4a methylation in cancer tissues did not show a significant difference from that in normal mucosae. In addition, associations between methylation of p16INK4a and clinical features such as age and cancer staging have been identified. Our results also found 14% p16INK4a gene hypermethylation in cancer tissues but none in normal tissues; however, p16INK4a methylation in cancer tissues was not significantly different from adjacent normal tissues. In addition, p16INK4a methylation in cancer tissues was not significantly associated with any clinical parameters. Although p16INK4a hypermethylation in cancer tissues in CRC patients seems to show a few differences among ethnicities, it remains a promising biomarker for CRC.

Wagner et al. [29] investigated RASSF1A promoter methylation in CRC and detected RASSF1A methylation in 80% (4/5) of CRC cell lines and 45% (13/29) of primary CRCs. Xu et al. [30] found that the frequency of RASSF1A methylation was extremely low in CRC. In our data, a similar low methylation frequency in the RASSF1A gene was observed in 20% of cancer tissues and 9% of adjacent normal tissues. However, in comparing cancer tissues and normal tissues, RASSF1A gene methylation showed significant differences. Also, the RASSF1A methylation in cancer tissues was 2-fold higher among the subjects over age 60. Age-related epigenetic defects have been proposed as potential sources of the field defects in colorectal carcinogenesis [31]. These data support the possibility that age-related RASSF1A methylation is involved in the pathways for the promotion of cancer progression of CRCs.

The methylation and subsequent loss of cell-cell adhesion may favor cancer progression and metastasis. Increasing hypermethylation of cell adhesion genes such as Twist1 and TIMP3 was observed in both adjacent normal and cancer tissues in our study. Therefore, the hypermethylation of these genes may play a potentially crucial role in CRC progression, most likely promoting cancer invasion. The presence of hypermethylation in adjacent normal tissues obtained from patients suggests that it might be an early event in the process of colorectal carcinogenesis. However, E-cadherin gene methylation frequency was not significantly different between cancer and normal colorectal tissues. Twist1 hypermethylation was more frequently found in cancer tissues than in their paired non-neoplastic tissues, suggesting that Twist1 might be considered a Type-C (cancer-related CpG methylation) agent with the potential to be used as an epigenetic cancer biomarker [32]. In other reported data, Twist1 hypermethylation was observed in colorectal specimens of 46 patients with cancer, but in none of the tissues from a nonmalignant control group [33]. Okada et al. [34] observed a higher Twist1 methylation level in

| Gene type | APC | p16INK4a | RASSF1A | Twist1 | TIMP3 | E-cadherin | ABCB1 | COX2 | Smad4 |
|-----------|-----|----------|---------|--------|-------|------------|-------|------|-------|
| p16INK4a  | -0.02 |          |         |        |       |            |       |      |       |
| RASSF1A   | 0.05  | 0.01     |         |        |       |            |       |      |       |
| Twist1    | 0.17  | -0.01    | 0.02    |        |       |            |       |      |       |
| TIMP3     | 0.25  | 0.22     | 0.02    | 0.16   |       |            |       |      |       |
| E-cadherin| 0.32  | 0.06     | 0.51    | 0.18   | 0.21  |            |       |      |       |
| ABCB1     | 0.14  | 0.00     | 0.09    | 0.38   | 0.24  | 0.27       |       |      |       |
| COX2      | 0.20  | 0.11     | -0.05   | 0.26   | 0.32  | 0.19       | 0.36  |      |       |
| Smad4     | 0.33  | 0.03     | -0.04   | 0.33   | 0.26  | 0.23       | 0.42  | 0.52 |

1 Moderate observer agreement.
Gene Promoter Methylation in Colorectal Cancer

colorectal adenoma and cancer tissues than in normal colorectal mucosa. However, there was no correlation between Twist1 methylation and expression. These results suggest the possibility that Twist1 methylation may not influence the promotion of CRC invasion by alternative compensatory molecular pathways, but the association of these findings with any clinical parameters must be confirmed. Aberrant expression of ABCB1 (MDR1) is associated with various carcinomas. The hypermethylation of normal CpG islands that were located in the promoter regions involved gene silencing at the transcriptional level [35]. We observed an increasing rate of ABCB1 hypermethylation in both adjacent normal and cancer tissues of CRC patients. The results suggest that ABCB1 hypermethylation is a candidate biomarker for CRC progression. However, ABCB1 promoter methylation in cancer tissues was not significantly associated with any clinical parameters.

TGF-β overexpression and Smad4 mutations or deletions have been directly correlated with CRC metastasis [36]. In the current study, the methylation of the Smad4 gene was observed in CRC tissues and adjacent normal tissues. Our finding that Smad4 hypermethylation occurred in CRC may support an association with cancer metastasis, which may ultimately lead to cancer development. However, Smad4 promoter methylation in CRC tissues was not significantly associated with any clinical parameters.

In conclusion, the key strength of the current research is that normal human tissues and CRC tissues are examined in an epigenetic study. The results of this study provide evidence that hypermethylation of cancer-associated genes may possibly serve as useful information regarding CRC cancer progression. Due to its small numbers, the current study has limitations as an association study; therefore, further studies with a sufficient number of subjects and additional candidate genes are required to confirm these findings.

ACKNOWLEDGEMENTS

This paper was supported by the Dong-A University Research Fund.

CONFLICT OF INTEREST

The authors have no conflicts of interest with the material presented in this paper.

REFERENCES

1. Grady WM, Carethers JM. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology 2008;135(4):1079-1099.
2. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin 1999;49(1):33-64.
3. Kim MS, Lee J, Sidransky D. DNA methylation markers in colorectal cancer. Cancer Metastasis Rev 2010;29(1):181-206.
4. Nishisho I, Nakamura Y, Miyoshi Y, Miki Y, Ando H, Horii A, et al. Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science 1991;253(5020):665-669.
5. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319(9):525-532.
6. Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 2000;16(4):168-174.
7. Rashid A, Shen L, Morris JS, Issa JP, Hamilton SR. CpG island methylation in colorectal adenomas. Am J Pathol 2001;159(3):1129-1135.
8. Esteller M, Sparks A, Toyota M, Sanchez-Cespedes M, Capella G, Peinado MA, et al. Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Res 2000;60(16):4366-4371.
9. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995;55(20):4525-4530.
10. Rodriguez J, Frigola J, Vendrell E, Risques RA, Fraga MF, Morales C, et al. Chromosomal instability correlates with genome-wide DNA demethylation in human primary colorectal cancers. Cancer Res 2006;66(17):8462-8468.
11. Feng Q, Hawes SE, Stern JE, Wiens L, Lu H, Dong ZM, et al. DNA methylation in tumor and matched normal tissues from non-small cell lung cancer patients. Cancer Epidemiol Biomarkers Prev 2008;17(3):645-654.
12. Friedrich MG, Weisenberger DJ, Cheng JC, Chandrasoma S, Siegmund KD, Gonzalez ML, et al. Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients. Clin Cancer Res 2004;10(22):7457-7465.
13. Chen G, Wu X, Yao Y, Zhou LF, Mao Y. Direct, real-time PCR (Methylight) assay for methylation of O6-methylguanine-DNA methyltransferase promoter in glioma. Chin Med J (Engl) 2009;122(11):1342-1345.
14. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C, Shiba-
ta D, et al. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 2000;28(8):E32.
15. Ogino S, Kawasaki T, Brahmandam M, Cantor M, Kirkner GJ, Spiegelman D, et al. Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. J Mol Diagn 2006;8(2):209-217.
16. Jin M, Kawakami K, Fukui Y, Tsukioka S, Oda M, Watanabe G, et al. Different histological types of non-small cell lung cancer have distinct folate and DNA methylation levels. Cancer Sci 2009;100(12):2325-2330.
17. Wolff EM, Liang G, Cortez CC, Tsai YC, Castelao JE, Cortessis VK, et al. RUNX3 methylation reveals that bladder tumors are older in patients with a history of smoking. Cancer Res 2008;68(15):6208-6214.
18. Hsu CY, Ho DM, Yang CF, Chiang H. Interobserver reproducibility of MIB-1 labeling index in astrocytic tumors using different counting methods. Mod Pathol 2003;16(9):951-957.
19. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet 1999;21(2):163-167.
20. Hiltunen MO, Alhonen L, Koistinaho J, Myohanen S, Paakkonen M, Marin S, et al. Hypermethylation of the APC (adenomatous polyposis coli) gene promoter region in human colorectal carcinoma. Int J Cancer 1997;70(6):644-648.
21. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Danenberg PV, Laird PW. CpG island hypermethylation in human colorectal tumors is not associated with DNA methyltransferase overexpression. Cancer Res 1999;59(10):2302-2306.
22. Chen J, Rocken C, Lofton-Day C, Schulz HU, Muller O, Kutzner N, et al. Molecular analysis of APC promoter methylation and protein expression in colorectal cancer metastasis. Carcinogenesis 2005;26(1):37-43.
23. Araki Y, Okamura S, Hussain SP, Nagashima M, He P, Shiseki M, et al. Regulation of cyclooxygenase-2 expression by the Wnt and ras pathways. Cancer Res 2003;63(3):728-734.
24. Castells A, Paya A, Alenda C, Rodriguez-Moranta F, Agrelo R, Andreu M, et al. Cyclooxygenase 2 expression in colorectal cancer with DNA mismatch repair deficiency. Clin Cancer Res 2006;12(6):1686-1692.
25. Lin SY, Yeh KT, Chen WT, Chen HC, Chen ST, Chiou HY, et al. Promoter CpG methylation of tumor suppressor genes in colorectal cancer and its relationship to clinical features. Oncol Rep 2004;11(2):341-348.
26. Burri N, Shaw P, Bouzourene H, Sordat I, Sordat B, Gillet M, et al. Methylation silencing and mutations of the p14ARF and p16INK4a genes in colon cancer. Lab Invest 2001;81(2):217-229.
27. Wiencke JK, Zheng S, Lafortuna E, Lafortuna MJ, Grudzen C, Wrensch MR, et al. Aberrant methylation of p16INK4a in anatomic and gender-specific subtypes of sporadic colorectal cancer. Cancer Epidemiol Biomarkers Prev 1999;8(6):501-506.
28. Ishiguro A, Takahata T, Saito M, Yoshiya G, Tamura Y, Sasaki M, et al. Influence of methylated p15 and p16 genes on clinicopathological features in colorectal cancer. J Gastroenterol Hepatol 2006;21(8):1334-1339.
29. Wagner KJ, Cooper WN, Grundy RG, Caldwell G, Jones C, Wadey RB, et al. Frequent RASSF1A tumour suppressor gene promoter methylation in Wilms’ tumour and colorectal cancer. Oncogene 2002;21(47):7277-7282.
30. Xu XL, Yu J, Zhang HY, Sun MH, Gu J, Du X, et al. Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis. World J Gastroenterol 2004;10(23):3441-3454.
31. Shen L, Kondo Y, Rosner GL, Xiao L, Hernandez NS, Vilaythong J, et al. MGMT promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst 2005;97(18):1330-1338.
32. Toyota M, Aihara N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A 1999;96(15):8681-8686.
33. Ruppenthal RD, Nicolini C, Filho AF, Meurer R, Damin AP, Rohe A, et al. TWIST1 promoter methylation in primary colorectal carcinoma. Pathol Oncol Res 2011;17(4):867-872.
34. Okada T, Suehiro Y, Ueno K, Mitomori S, Kaneko S, Nishioka M, et al. TWIST1 hypermethylation is observed frequently in colorectal tumors and its overexpression is associated with unfavorable outcomes in patients with colorectal cancer. Genes Chromosomes Cancer 2010;49(5):452-462.
35. El-Osta A, Kantharidis P, Zalcberg JR, Wolfe AP. Precipitous release of methyl-CpG binding protein 2 and histone deacetylase 1 from the methylated human multidrug resistance gene (MDR1) on activation. Mol Cell Biol 2002;22(6):1844-1857.
36. Gulubova M, Manolova I, Ananiev J, Julianov A, Yovchev Y, Pleva K. Role of TGF-beta1, its receptor TGFbetaRII, and Smad proteins in the progression of colorectal cancer. Int J Colorectal Dis 2010;25(5):591-599.